Filing Details

Accession Number:
0000947871-16-001283
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-20 17:40:17
Reporting Period:
2016-06-16
Filing Date:
2016-06-20
Accepted Time:
2016-06-20 17:40:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
806888 Response Biomedical Corp RBM Services-Testing Laboratories (8734) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055949 D Samuel Isaly 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1432241 Orbimed Capital Gp Iii Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1491520 Orbimed Asia Gp, Lp 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1491569 Ltd Advisors Orbimed 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-06-16 556,339 $0.56 3,604,266 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2016-06-16 5,294 $0.56 34,291 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2016-06-16 331,225 $0.56 2,149,902 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Footnotes
  1. Represents shares of common stock of the Issuer ("Shares") purchased by OrbiMed Private Investments III, LP ("OPI III") in a secondary offering pursuant to a Subscription Agreement dated as of June 16, 2016 (the "Offering").
  2. Represents Shares purchased by OrbiMed Associates III, LP ("OA III") in the Offering.
  3. Represents Shares purchased by OrbiMed Asia Partners, L.P. ("OAP") in the Offering.
  4. This report on Form 4 is jointly filed by OrbiMed Capital GP III LLC ("OrbiMed Capital"), OrbiMed Advisors LLC ("OrbiMed Advisors"), Samuel D. Isaly ("Isaly"), OrbiMed Advisors Limited ("OrbiMed Limited") and OrbiMed Asia GP, L.P. ("OrbiMed Asia"). Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  5. The reporting persons have designated two representatives, currently Jonathan Wang and Peter Thompson, all of whom are employees of OrbiMed Advisors, to serve on the Issuer's board of directors. Each such representative disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that any of them are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  6. These Shares are held of record by OPI III and may be deemed to be indirectly beneficially owned by OrbiMed Capital, OrbiMed Advisors and Isaly. OrbiMed Capital is the sole general partner of OPI III. OrbiMed Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital. Pursuant to those relationships, OrbiMed Capital and OrbiMed Advisors have discretionary investment management authority with respect to the assets of OPI III. Such authority includes the power to vote and otherwise dispose of the securities held by OPI III. Isaly, a natural person, is the managing member of, and holder of a controlling interest in, OrbiMed Advisors. As a result, Isaly, OrbiMed Advisors and OrbiMed Capital share power to direct the vote and to direct the disposition of the securities held by OPI III.
  7. These Shares are held of record by OA III and may be deemed to be indirectly beneficially owned by OrbiMed Advisors and Isaly. OrbiMed Advisors is the sole general partner of OA III, and Isaly is the managing member of, and holder of a controlling interest in, OrbiMed Advisors. As a result, Isaly and OrbiMed Advisors share power to direct the vote and to direct the disposition of the securities held by OA III.
  8. These Shares are held of record by OAP and may be deemed to be indirectly beneficially owned by OrbiMed Asia and OrbiMed Limited. OrbiMed Asia is the sole general partner of OAP and OrbiMed Limited is the sole general partner of OrbiMed Asia. As a result, OrbiMed Asia has the power to direct the vote and to direct the disposition of the securities held by OAP and such power is exercised through OrbiMed Limited.